Antiplatelet Therapy in Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis
Rawan Mohammed Alzahrani1, Terad Talmesany2, Atheer Atiah Alghamdi1
1Faculty of Medicine, Al Baha University, Al Baha, Saudi Arabia.
Insights
Clopidogrel monotherapy may be superior to aspirin for stable coronary artery disease (CAD). Anticoagulant monotherapy is recommended for atrial fibrillation with CAD, while intensified therapies require careful patient selection due to bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Stable coronary artery disease (CAD) impacts millions globally.
- Emerging evidence questions aspirin monotherapy's standard role in antithrombotic treatment.
- P2Y12 inhibitors and direct oral anticoagulants are key alternatives.
Purpose of the Study:
- To assess antiplatelet strategies in stable CAD.
- Compare monotherapy efficacy and safety.
- Evaluate oral anticoagulant strategies for atrial fibrillation with CAD.
- Examine intensified and diabetes-specific therapies.
Main Methods:
- Systematic search of RCTs and observational studies up to May 2025.
- Primary outcomes: major adverse cardiovascular events (MACE) and major bleeding.
- Utilized random-effects meta-analyses, network meta-analysis, and meta-regression.
Main Results:
- Clopidogrel showed superiority over aspirin in MACE and bleeding (2 RCTs).
- Anticoagulant monotherapy demonstrated better efficacy and safety than combination therapy in atrial fibrillation with CAD (2 RCTs).
- Intensified therapy reduced MACE but increased bleeding (4 RCTs).
Conclusions:
- Clopidogrel monotherapy may offer advantages over aspirin in stable CAD.
- Anticoagulant monotherapy is supported for atrial fibrillation with stable CAD post-revascularization.
- Intensified strategies benefit select high-risk patients, requiring careful risk-benefit assessment.
Background:
Stable coronary artery disease (CAD) affects around 200 million people worldwide. Recent evidence with P2Y12 inhibitors, direct oral anticoagulants, and combination strategies has challenged aspirin monotherapy as the standard antithrombotic approach.
Objectives:
The purpose of this study was to evaluate antiplatelet strategy efficacy and safety in stable CAD, focusing on monotherapy comparisons, oral anticoagulant strategies in atrial fibrillation with CAD, intensified therapy in high-risk patients, and diabetes-specific strategies.
Methods:
We searched databases through May 13, 2025, including randomized controlled trials (RCTs) and observational studies. Primary outcomes were major adverse cardiovascular events (MACEs) and major bleeding. We performed random-effects meta-analyses, network meta-analysis, and meta-regression.
Results:
Twenty-three studies (437,662 patients; 13 RCTs, 6 observational, 4 post-hoc) were included. Two RCTs (HOST-EXAM, CAPRIE; n = 24,623) demonstrated clopidogrel superiority over aspirin for MACE (hazard ratio [HR] 0.73 [0.59-0.90]) and bleeding (HR 0.63 [0.41-0.97]). In atrial fibrillation with stable CAD, 2 RCTs (AFIRE, EPIC-CAD; n = 3,276) showed anticoagulant monotherapy had superior efficacy (HR 0.61 [0.49-0.76]) and safety (HR 0.52 [0.36-0.76]) vs combination therapy; observational data (Lamberts; n = 8,700) showed discordant results. Four RCTs showed intensified therapy reduced MACE (HR 0.85 [0.80-0.91]) but increased bleeding (HR 1.85 [1.65-2.07]).
Conclusions:
Based on 2 RCTs, clopidogrel monotherapy may offer advantages over aspirin in stable CAD. RCT evidence supports anticoagulant monotherapy in atrial fibrillation with stable CAD beyond 12 months post-revascularization. Intensified strategies may benefit selected high-risk patients though narrow therapeutic margins (number needed to treat 91 vs number needed to harm 85) necessitate careful patient selection.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care


